Evidence map›Paper›PMID 29539266›Full record

ArticleBiomacromolecules2018

Optimizing Glutaraldehyde-Fixed Tissue Heart Valves with Chondroitin Sulfate Hydrogel for Endothelialization and Shielding against Deterioration.

Mario Lopez-Moya, Pedro Melgar-Lesmes, Kumaran Kolandaivelu, Jose María de la Torre Hernández, Elazer R Edelman, Mercedes Balcells

Open access · greenAbstract read
In one paragraph

Article in Biomacromolecules, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 94 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Nanomedicines for cardiovascular disease.Nature cardiovascular research · 2023
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Mario Lopez-MoyaMassachusetts Institute of Technology, Institute for Medical Engineering and Science , Cambridge , Massachusetts 02139 , United States.
Pedro Melgar-LesmesMassachusetts Institute of Technology, Institute for Medical Engineering and Science , Cambridge , Massachusetts 02139 , United States.ORCID 0000-0002-2009-5911
Kumaran KolandaiveluMassachusetts Institute of Technology, Institute for Medical Engineering and Science , Cambridge , Massachusetts 02139 , United States.
Jose María de la Torre HernándezHospital Marqués de Valdecilla , Santander 39008 , Spain.
Elazer R EdelmanMassachusetts Institute of Technology, Institute for Medical Engineering and Science , Cambridge , Massachusetts 02139 , United States.
Mercedes BalcellsMassachusetts Institute of Technology, Institute for Medical Engineering and Science , Cambridge , Massachusetts 02139 , United States.
Brigham and Women's Hospital · USInstitut Químic de Sarrià · ESFundació Clínic per a la Recerca Biomèdica · ESMarqués de Valdecilla University Hospital · ES

Funding

Vascular Drug Delivery - Supplement for EquipmentR01GM049039 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI EDELMAN, ELAZER R · 1994 to 2019
$8.9M
NIGMS NIH HHS R01 GM049039
6 · The paper itself

Abstract

Porcine glutaraldehyde-fixed pericardium is widely used to replace human heart valves. Despite the stabilizing effects of glutaraldehyde fixation, the lack of endothelialization and the occurrence of immune reactions contribute to calcification and structural valve deterioration, which is particularly significant in young patients, in whom valve longevity is crucial. This report shows an optimization system with which to enhance endothelialization of fixed pericardium to mimic the biological function of a native heart valve. The glutaraldehyde detoxification, together with the application of a biodegradable methacrylated chondroitin sulfate hydrogel, reduces aldehydes cytotoxicity, increases the migration and proliferation of endothelial cells and the recruitment of endothelial cell progenitors, and confers thromboresistance in fixed pericardium. The combination of glutaraldehyde detoxification and a coating with chondroitin sulfate hydrogel promotes in situ mechanisms of endothelialization in fixed pericardium. We offer a new solution for improving the long life of bioprosthetic valves and exploring the means of making valves suitable to endothelialization.

Indexed as

AnimalsCell MovementCell ProliferationChondroitin SulfatesClinical DeteriorationDisease Models, AnimalEndothelial CellsGlutaralHeart ValvesHumansHydrogel, Polyethylene Glycol DimethacrylatePericardiumSwineChondroitin SulfatesGlutaralHydrogel, Polyethylene Glycol Dimethacrylate

Identifiers

PMID29539266
PMCPMC6198652
OpenAlexW2790010649

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.